Congratulations to Paul Sondel, MD, PhD, who was awarded a Research Grant from St. Baldrick’s Foundation in the amount of $105,773. In this 1-year project, entitled “Finding the Target of Beneficial Pre-existing Anti-Therapeutic Antibodies,” investigators will use gene sequencing and immune-assays to determine the target for Pre-existing Anti-Therapeutic Antibodies (PATA) on IgG1 monoclonal-antibody (mAb) therapy; and to use ELISA assays to confirm the presence and significance of PATA in other clinical studies. The overall goal is to determine whether these PATA might be used to improve outcome for children receiving mAb treatment for cancer, either by using it as a selection criterion, or by using it to modify the design of mAb-based therapeutics or clinical trials that test them.